SCHEMBL1973575

SCHEMBL1973575

COc1cc2oc(-c3cc(O)c(O)c(O)c3)cc(=O)c2c(O)c1CCCCCCCCCCCCCO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
MAPT P10636 3/20 0.53
RECQL P46063 2/20 0.53
POLB P06746 2/20 0.53
AKR1B1 P15121 1/20 0.53
MAOA P21397 1/20 0.53
MAPK8 P45983 1/20 0.53
AURKA O14965 1/20 0.52
CYP1A1 P04798 1/20 0.52
KDR P35968 1/20 0.52
FLT3 P36888 1/20 0.52
CYP1B1 Q16678 1/20 0.52
AURKB Q96GD4 1/20 0.52
ABCB1 P08183 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
CYP3A4 P08684 1/20 0.50
PIM1 P11309 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1977889 1.00 KDM4E (0.53) KDM4EMAPTRECQLPOLBAKR1B1
SCHEMBL1976594 0.91 KDM4E (0.59) KDM4EMAPTRECQLPOLBMEN1
SCHEMBL1421590 0.91 KDM4E (0.59) KDM4EMAPTRECQLPOLBMEN1
SCHEMBL1975034 0.88 POLB (0.64) KDM4EMAPTPOLBAURKACYP1A1
SCHEMBL1975441 0.88 POLB (0.64) KDM4EMAPTPOLBAURKACYP1A1
SCHEMBL1975654 0.87 PTPRS (0.53) KDM4EMAPTRECQLPOLBCYP1A1
SCHEMBL1977221 0.87 PTPRS (0.53) KDM4EMAPTRECQLPOLBCYP1A1
SCHEMBL1974901 0.86 ABCB1 (0.47) KDM4EMAPTPOLBAURKACYP1A1
SCHEMBL1975096 0.86 ABCB1 (0.47) KDM4EMAPTPOLBAURKACYP1A1
SCHEMBL1973514 0.83 ABCB1 (0.64) KDM4EMAPTRECQLPOLBAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 US disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA KDM4E 2608/4885MAPT 243/4885RECQL 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.